Regeneron Pharmaceuticals Inc (WBO:REGN)
€ 910.2 5.8 (0.64%) Market Cap: 99.67 Bil Enterprise Value: 92.44 Bil PE Ratio: 28.90 PB Ratio: 3.99 GF Score: 77/100

Regeneron Pharmaceuticals Inc at Barclays Biopharmaceuticals CEO/CFO Conference Call Series Transcript

May 17, 2019 / 03:00PM GMT
Release Date Price: €276.83 (-0.26%)
Operator

Good morning. My name is Latania, and I will be your conference operator today. At this time, I would like to welcome everyone to the Barclays Biopharma CEO/CFO Conference Call Series with Regeneron. (Operator Instructions)

I would now like to turn the call over to your host, Mr. Geoff Meacham. Sir, you may begin.

Geoffrey Christopher Meacham;Robert E. Landry
Barclays Bank PLC, Research Division - MD & Senior Research Analyst;Regeneron Pharmaceuticals, Inc. - Executive VP

Okay. Great. Thanks, Latania, and thanks, everyone, for joining us. I'm Geoff Meacham. I'm the senior biopharma analyst here at Barclays. My team is on the phone as well. We have Greg, Scott, [Olivia] and Jason, and we're thrilled to have Regeneron as part of our CEO/CFO call series. And we have a big crew today. We have Marion McCourt who's Senior Vice President, Head of Commercial. We have Bob Landry who's Executive Vice President and CFO. And then we have Jay Markowitz as well who is Senior Vice President, Portfolio Management. So welcome, guys.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot